CagriSema
CagriSema is an investigational combination therapy consisting of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist. It is being developed by Novo Nordisk for the treatment of obesity and type 2 diabetes.
CagriSema is a fixed-dose combination injectable peptide consisting of semaglutide, a GLP-1 receptor agonist, and cagrilintide, a long-acting amylin analogue. It works by targeting dual satiety pathways in the brain to reduce appetite and slow gastric emptying, primarily used for the treatment of obesity and type 2 diabetes.
Overview
CagriSema is a fixed-ratio co-formulation of two distinct peptide-based therapeutics: cagrilintide, a long-acting analog of the pancreatic hormone amylin, and semaglutide, a GLP-1 receptor agonist already approved for obesity and type 2 diabetes under the brand names Ozempic and Wegovy. Developed by Novo Nordisk, CagriSema is administered as a once-weekly subcutaneous injection and is designed to target complementary appetite-regulating pathways for enhanced weight loss and glycemic control.
Cagrilintide acts on amylin receptors in the area postrema and other brainstem regions to promote satiety, slow gastric emptying, and suppress glucagon secretion. Semaglutide activates GLP-1 receptors to stimulate insulin secretion, reduce appetite, and decrease food intake through central and peripheral mechanisms. The combination leverages the synergistic effects of engaging both the amylin and GLP-1 signaling pathways simultaneously, which preclinical and clinical data suggest produces greater reductions in body weight than either agent alone.
Phase 3 clinical trials, including the REDEFINE program, have evaluated CagriSema across populations with obesity and type 2 diabetes. Early results demonstrated mean body weight reductions exceeding 20% from baseline, positioning CagriSema among the most effective pharmacological weight-loss interventions studied to date. The safety profile has been generally consistent with that of GLP-1 receptor agonists, with gastrointestinal side effects being the most commonly reported adverse events. Regulatory submissions are anticipated based on ongoing trial outcomes.
Mechanism of Action
Dual GLP-1/Amylin Receptor Agonism
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin receptor agonist) and semaglutide (a GLP-1 receptor agonist), designed to target complementary appetite-regulatory pathways for additive weight loss. Semaglutide binds the GLP-1 receptor (GLP-1R) with 94% structural homology to native GLP-1 but with an acylated C18 fatty acid chain enabling albumin binding and a half-life of approximately 7 days. Cagrilintide is an acylated analog of human amylin with similarly extended pharmacokinetics (PMID: 36806606).
Semaglutide — GLP-1R Signaling Cascade
Semaglutide activates GLP-1R on pancreatic beta cells, hypothalamic neurons, and vagal afferents. Beta-cell GLP-1R activation triggers Gs/cAMP/PKA/Epac2 signaling, potentiating glucose-stimulated insulin secretion and suppressing glucagon release. In the hypothalamus, GLP-1R activation in the arcuate nucleus stimulates POMC/CART anorexigenic neurons and inhibits NPY/AgRP orexigenic neurons. GLP-1R in the area postrema and nucleus tractus solitarius mediates satiety through vagal afferent signaling and delayed gastric emptying (PMID: 28741625).
Cagrilintide — Amylin/Calcitonin Receptor Pathway
Cagrilintide activates the amylin receptor (AMY1-3), which consists of the calcitonin receptor (CTR) complexed with receptor activity-modifying proteins (RAMP1-3). Amylin receptor activation in the area postrema reduces meal size and eating rate through distinct neuronal populations from those targeted by GLP-1. The CTR/RAMP complex signals through Gs/cAMP and Gq/PKC pathways, activating downstream ERK1/2 and CGRP signaling cascades. Cagrilintide also promotes satiety through hindbrain noradrenergic neurons projecting to the hypothalamus (PMID: 34986330).
Synergistic Weight Loss Mechanism
The combination achieves greater weight loss than either agent alone because GLP-1R and amylin receptors engage non-overlapping neuronal circuits in the hindbrain and hypothalamus. Phase 2 trials demonstrated up to 15-17% body weight reduction at 32 weeks with CagriSema versus ~8-10% with either monotherapy (PMID: 36806606).
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Reported Effects
Strength Gains:: Consistently rated as the most effective legal supplement for increasing 1RM (one-rep max) and explosive power.. Mental Stamina:: High-dose protocols (15g+) appear efficacious for users dealing with neurological fatigue or 'long-COVID' symptoms.. Consistency:: Benefits are most prominent after 2-4 weeks of daily use once muscle stores are fully saturated.. Reliability:: Unlike many 'hyped' supplements, users frequently note this is one of the few that provides measurable objective results.
- Consistently rated as the most effective legal supplement for increasing 1RM (one-rep max) and explosive power.
- High-dose protocols (15g+) appear efficacious for users dealing with neurological fatigue or 'long-COVID' symptoms.
- Benefits are most prominent after 2-4 weeks of daily use once muscle stores are fully saturated.
- Unlike many 'hyped' supplements, users frequently note this is one of the few that provides measurable objective results.
Safety Profile
Common Side Effects
- Nausea is the most frequently reported adverse effect, occurring in approximately 40-60% of patients during titration
- Vomiting and diarrhea, often dose-dependent and typically diminishing over weeks
- Decreased appetite and early satiety, which contribute to the weight-loss mechanism
- Abdominal pain, bloating, and flatulence
- Constipation
- Headache, dizziness, and fatigue
- Injection site reactions including redness, swelling, and itching (administered subcutaneously)
- Dyspepsia and gastroesophageal reflux
Serious Adverse Effects
- Pancreatitis: patients should be monitored for persistent severe abdominal pain; discontinue if pancreatitis is suspected
- Gallbladder events including cholelithiasis (gallstones) and cholecystitis, occurring at higher rates with rapid weight loss
- Acute kidney injury, potentially secondary to dehydration from gastrointestinal fluid losses
- Hypoglycemia risk, particularly in patients co-administered insulin or sulfonylureas
- Thyroid C-cell tumors: GLP-1 receptor agonists carry a boxed warning based on rodent studies showing medullary thyroid carcinoma; human relevance is uncertain but the warning applies
- Suicidal ideation: regulatory agencies are monitoring reports, though a causal link has not been established
- Diabetic retinopathy complications may occur with rapid glycemic improvement
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide, cagrilintide, or any excipients
- History of pancreatitis (relative contraindication; use with extreme caution)
- Severe gastrointestinal disease including gastroparesis
- Pregnancy and breastfeeding: CagriSema is contraindicated; discontinue at least 2 months before planned pregnancy
Drug Interactions
- Insulin and sulfonylureas: increased hypoglycemia risk; dose reduction of these agents is typically required
- Oral medications: GLP-1 receptor agonists delay gastric emptying, potentially affecting absorption kinetics of co-administered oral drugs
- Oral contraceptives: reduced absorption efficacy is possible; consider alternative contraception methods
- Warfarin: monitor INR more frequently due to potential altered absorption
Special Populations
- Not approved for use in pediatric populations
- Elderly patients may experience more pronounced gastrointestinal side effects and dehydration risk
- Renal impairment: use with caution and monitor kidney function
- Hepatic impairment: limited data; use with caution in severe hepatic disease
Pharmacokinetic Profile
CagriSema — Pharmacokinetic Curve
SubcutaneousQuick Start
- Typical Dose
- 5g daily is the most common and sustainable dose for general health and athletic performance.
Safety Profile
Common Side Effects
- Weight Gain:: Initial 2-5 lbs increase due to intracellular water retention, which some users mistake for fat gain.
- Digestive Distress:: Occasional bloating or diarrhea if taken in large doses on an empty stomach without enough water.
- Mineral Depletion:: While not common for creatine, users of other long-term supplements (like NAC) warn about monitoring trace minerals like zinc.
- Hair/Skin Changes:: Anecdotal reports of changes are rare but frequently discussed; scientific literature generally does not support a causal link.
References (4)
- [2]Creatine Supplementation: An Update
→ Creatine consistently increases lean muscle mass and exercise capacity while offering potential neuroprotective and recovery benefits.
- [3]Effects of creatine supplementation on muscle strength gains—a meta-analysis and systematic review
→ A meta-analysis confirms that creatine significantly elevates intramuscular stores to enhance energy availability during high-intensity training.
- [4]Single dose creatine improves cognitive performance and induces changes in cerebral high energy phosphates during sleep deprivation
→ High-dose creatine was found to partially reverse cognitive fatigue and metabolic changes in the brain during periods of acute sleep deprivation.
- [1]Creatine supplementation is safe, beneficial throughout the lifespan, and should not be restricted
→ Recent comprehensive reviews confirm that creatine is safe for long-term use across all ages and provides significant physical and cognitive benefits.